MiR-572 promotes the development of non-small cell lung cancer by targeting KLF2 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35587058/
Objective: The aim of this study was to uncover the role of miR-572 in regulating proliferative and migratory abilities in non-small cell lung cancer (NSCLC) and the possible mechanism. Patients...
Conclusions: MiR-572 is closely linked to metastasis and prognosis in NSCLC patients, and it promotes the malignant development of NSCLC via targeting KLF2.
Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy
Source : https://www.tandfonline.com/doi/full/10.1080/07853890.2022.2071977
Abstract Abstract Vascular endothelial growth factor (VEGF) is a critical regulator of malignant pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and apatinib (APA) are novel VEGF blockers...
Conclusions: Mechanistically, LLC-induced MPE was inhibited by targeting the VEGF-MEK/ERK pathways. Further studies are needed to establish the synergistic therapeutic effect of these drugs in NSCLC patients with MPE.
Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma
Source : https://www.sciencedirect.com/science/article/abs/pii/S0009279722001715?via=ihub
Tumor inhibitors such as and , (LUSC) patient. Thus, identification of effective and safe tumor angiogenesis inhibitor for NSCLC therapy is warranted. is a angiogenesis Bevacizumab, Endostar have been applied...
Conclusion: Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma.
Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268073
Lung cancer is responsible for the most cancer-related mortality worldwide and the mechanism of its development is poorly understood. Proteomics has become a powerful tool offering vital knowledge related to...
Conclusion: We identified several proteins that are important for the better characterization of tumor development and molecular specificity of both lung cancer subtypes. We also identified proteins that may be important as biomarkers and/or targets for anticancer therapy.
-
NSCLC Connect3yrKey Points • Source: PLOS ONE • Conclusion: “We identified several proteins that are important for the better characterization of tumor development and molecular specificity of both lung cancer subtypes. We also identified proteins Show More
Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35501907/
doi: 10.1186/s13046-022-02369-3. 1 Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Tongjiaxiang #24, Nanjing, 210009, Jiangsu, China. 2 Department of...
Conclusion: Aumolertinib-pemetrexed combined therapy is promising for EGFR mutant NSCLC but only in right administration sequence. P-A could become an advantageous combination strategy in clinical with synergistic inhibition of tumor growth and metastasis.